First Made-in-India 'Digital Pill' by Wellthy Therapeutics to Undergo Clinical Trial for Diabetes

MUMBAI, November 16, 2017 /PRNewswire/ --

Asia's largest diabetes organization, RSSDI partners with Wellthy Therapeutics to launch South Asia's First-of-its-kind Clinical Trial for Diabetes

The #WeDiDiT (Wellthy Digital Diabetes Therapy) trial is all set to prove the efficacy of its 16-week structured diabetes management programme delivered through a mobile app. The trial was launched by Past President of RSSDI, Dr. Sarita Bajaj at the RSSDI Annual Conference in Bhubaneswar in the first week of November. The outcome of this multi-center randomized control trial will be measured by the HbA1C levels of patients before and after the trial.

     (Photo: )
As part of the programme, personalized diabetes self-management education and real time coaching will be offered through dedicated health coaches and an artificial intelligence powered chat bot, to engage and improve the health of patients with type 2 diabetes by facilitating behavior change.

Commenting on the first-of-its-kind initiative in India, Mr. Abhishek Shah, Co-founder and CEO of Wellthy Therapeutics said, "On World Diabetes Day, we re-affirm our commitment to solve for the diabetes epidemic. Conducting a clinical trial on a mobile app is unprecedented in India and we are extremely optimistic about the study outcomes. While the Wellthy app has already demonstrated its efficacy in various pilot studies, this formal clinical trial conducted with the RSSDI will provide the evidence necessary to show that digital therapeutics have the potential to improve the lives of diabetes patients in India and around the world."

Dr. Rajeev Chawla, Current President Elect of RSSDI said, "The need for digital interventions in diabetes care is more now than ever, especially in India. The Wellthy Diabetes intervention is an innovation born out of India, for Indians and South Asians. This clinical trial holds tremendous potential in terms of changing outcomes for people living with diabetes by making it easier for them to manage their blood sugar levels and improving their overall quality of life."

Dr. Sarita Bajaj, the Past President of RSSDI added, "Wellthy and RSSDI together are set to launch the first ever landmark trial in South Asia to test the impact of using digital technologies to manage diabetes, which is the need of the hour today. The RSSDI doctors conducting the trial will offer the app to their patients to download, and as the intervention progresses, study how it impacts their patients and their clinical management. "

Diabetes is a chronic disease that requires treatment for life. This makes adherence to blood sugar controlling lifestyle modifications such as healthy eating, physical activity, and timely medication mandatory. It is common for patients to make an error in their diabetes management by either overeating carbohydrates on a particular day, not exercising enough, or forgetting to take their medicine.

"From a patient safety perspective, the benefits offered by digital therapeutics are immense. Diabetes care needs to be continual versus the episodic care available today, and patient journey data like this is essential for the treating doctor to further personalize advice and pharmacological care. It is the ultimate win-win designed with a patient-centric approach, enhancing quality of care, access and affordability," added Mr. Shah.

The diabetes burden in India is enormous. As per data by the International Diabetes Federation, there are an estimated 69.1 million people living with diabetes in India and another 77.2 million with pre-diabetes which is a high-risk condition for diabetes and cardio-vascular disease. The need of the hour is to manage this epidemic using behavioural change in the population and only technology seems like the likely answer to scale it up at an economical cost.

About RSSDI: 
Research Society for the Study of Diabetes in India (RSSDI), founded in 1972, is the largest organisation of diabetes health care professionals and researchers in Asia. Currently, it has more than 5500 life members representing 29 Indian States and Union Territories. RSSDI is actively involved in updating the knowledge and skills of physicians. Each chapter carries out independent activities including CMEs for member physicians, local research grants, and awareness programs for public as well as diabetes patients. RSSDI is also actively involved in diabetes awareness programs which focus on creating awareness about various aspects of diabetes among diabetes patients and their families and population at large. For more information, please visit

About Wellthy Therapeutics:   

Wellthy Therapeutics is a digital therapeutics company that uses artificial intelligence (AI) and patient centric design to improve patient outcomes for all stakeholders in diabetes care. It facilitates behaviour change and self-management for patients, while helping physicians to enable continual care using technology and solve for the 8750+ hours that patients don't have access to healthcare. Wellthy Therapeutics has commercialized a digital therapeutic for patients with type 2 diabetes that is the first endorsed digital diabetes intervention by Asia's largest Diabetes Association (RSSDI). 

Wellthy's clinical pilots and data have shown early validation, and it has a proven record of publishing clinical evidence. It recently published real world data at the RSSDI 44th Annual conference in Hyderabad, India & the RSSDI 45th Annual conference in Bhubhaneshwar, at the AACE 26th Annual Congress in Austin, TX, and at ADA 77th Scientific Sessions in San Diego, CA.  

For more information, visit

Media Contact: 
Dr Reshma P Nayak
VP - Marketing
Wellthy Therapeutics Pvt Ltd

SOURCE Wellthy Therapeutics

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos and customised feeds just for media.

View and download archived video content distributed by MultiVu on The Digital Center.


Get content for your website

Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Start today.



Contact PR Newswire

Send us an email at or call us at +91 22 6169 6000



Become a PR Newswire client

Request more information about PR Newswire products & services or call us at +91 22 6169 6000


  1. Products & Services
  2. Knowledge Centre
  3. Browse News Releases
  4. Contact PR Newswire